Myasthenia Gravis Treatment: From Steroids to Biologics

Myasthenia gravis treatment follows a layered strategy, starting with a medication that improves nerve-to-muscle signaling and escalating through immune-suppressing drugs, surgery, and newer targeted biologics depending on how severe the disease is and how it responds. No single therapy works for everyone, and the combination that keeps one person in remission may barely touch another’s symptoms. The treatment landscape has shifted dramatically in recent years, with several new drug classes reaching approval and early-phase research exploring therapies that could reset the immune system entirely.

Symptom Control With Pyridostigmine

The usual starting point is pyridostigmine, a drug that blocks the enzyme responsible for breaking down the chemical messenger acetylcholine at the junction between nerves and muscles. By letting more acetylcholine accumulate, pyridostigmine temporarily strengthens muscle contractions. It does not change the underlying immune attack, so it is a symptomatic fix rather than a disease-modifying one. For people with mild disease, pyridostigmine alone can be enough to manage day-to-day weakness and fatigue.¹

Side effects are mostly gastrointestinal: cramping, diarrhea, and nausea at higher doses. Most people find a tolerable dose, but there is a ceiling to what pyridostigmine can do. When weakness progresses beyond mild droopy eyelids or occasional difficulty chewing, the next tier of treatment involves suppressing the immune system itself.

Corticosteroids and the Paradox of Early Worsening

Oral corticosteroids, usually prednisone, remain the most widely used first-line immunosuppressive treatment. They are effective for most people and have decades of clinical experience behind them. The catch is a well-documented phenomenon: some patients get temporarily worse in the first few weeks of starting steroids, a paradoxical flare that can range from mild increased weakness to a dangerous crisis requiring hospitalization.

A systematic review of 27 publications found that the rate of this initial worsening varies by the steroid used and the dose. The exacerbation rate is highest with cortisone, intermediate with prednisone, and lowest with methylprednisolone. High daily doses are more likely to trigger a flare than low-dose or slow-escalation approaches, though most of these flares turn out to be mild to moderate in severity. Risk factors include older age, generalized disease, bulbar symptoms, the presence of a thymoma, and prior thymectomy.² A separate study pegged the rate at about one in four patients, with thymoma-associated or early-onset disease, starting doses of 40 mg or more per day, and upper-limb weakness identified as independent predictors.³

One strategy to reduce this risk is giving intravenous immunoglobulin (IVIG) before starting prednisone. In a study of 45 patients with generalized MG who received IVIG before their first prednisone course, only about 2% experienced a paradoxical worsening, compared with a historically reported rate of 42%. Nearly 87% improved clinically over the six-week monitoring period.⁴ That’s a striking difference, though it comes from a single-arm trial compared against historical controls, so it should be interpreted with some caution.

Beyond the initial worsening, long-term steroid use carries its own well-known problems: weight gain, bone thinning, high blood sugar, mood changes, and increased infection risk. This is why clinicians almost always try to taper steroids to the lowest effective dose and add a steroid-sparing agent.

Steroid-Sparing Drugs

Azathioprine and mycophenolate mofetil are the two most commonly prescribed steroid-sparing immunosuppressants. Both work by broadly dampening the immune system’s ability to produce the antibodies that attack the neuromuscular junction. They take months to reach full effect, which is why steroids are usually maintained during the ramp-up period. The newer complement inhibitors appear to reduce steroid doses faster than either of these older agents. A recent study found that complement inhibitors achieved statistically greater steroid reductions at three, six, and nine months compared with mycophenolate, and at six months compared with azathioprine.⁵

Thymectomy

The thymus gland, located behind the breastbone, plays a role in the immune dysfunction behind MG. Anyone with a thymic tumor (thymoma) should have the gland removed, but thymectomy also benefits many patients without a tumor. A landmark randomized trial published in the New England Journal of Medicine showed that patients who had thymectomy plus prednisone had better symptom scores over three years than those on prednisone alone, needed lower steroid doses (an average of 44 mg on alternate days versus 60 mg), were less likely to need azathioprine (17% versus 48%), and were hospitalized for flares far less often (9% versus 37%).⁶

A five-year extension of that same trial confirmed the benefits held up and actually widened over time. Thymectomy patients continued to have better symptom scores and needed roughly half the steroid dose of the prednisone-only group. Hospitalizations for exacerbations remained significantly less common: 6% versus 30%.⁷ The surgery is most clearly helpful in people who test positive for acetylcholine receptor antibodies; evidence for those with MuSK antibodies does not support thymectomy, and current guidelines advise against it in that subgroup.⁸

When Things Get Urgent

A myasthenic crisis, where respiratory muscles weaken to the point of needing ventilatory support, is a medical emergency. The two rapid-rescue treatments are plasma exchange (PLEX) and intravenous immunoglobulin (IVIG). Plasma exchange physically filters harmful antibodies from the blood, while IVIG floods the system with normal antibodies that interfere with the autoimmune process.

A head-to-head trial found that about 69% of patients improved on IVIG and 65% on PLEX, with similar duration of effect for both treatments.⁹ However, an earlier retrospective study of myasthenic crises specifically suggested plasma exchange had a slight edge in ventilatory recovery at two weeks and functional outcomes at one month, although it also came with a higher complication rate.¹⁰ In practice, the choice often depends on what’s available, what the patient can tolerate, and whether they have reliable intravenous access for the multi-session plasma exchange protocol.

Targeted Biologics

The last several years have brought a wave of new drugs that hit narrower immune targets than traditional immunosuppressants, offering better efficacy for some patients with fewer broad side effects.

Complement Inhibitors

Eculizumab and ravulizumab both block a protein called C5 in the complement cascade, a branch of the immune system that directly damages the neuromuscular junction in people with acetylcholine receptor antibodies. A comparison of complement inhibitors found that all of them produced similar improvements across multiple clinical scales, with no statistically significant differences among the individual drugs.¹¹ Ravulizumab, which requires infusions every eight weeks instead of every two, showed improvements in daily-living and strength scores within one week of the first dose, sustained through six months in a placebo-controlled trial.¹²

These drugs only work in the subset of MG caused by acetylcholine receptor antibodies, which is the majority but not all patients. They also carry a meaningful risk of meningococcal infection because C5 is part of the immune defense against that bacterium, so vaccination before starting treatment is mandatory.

FcRn Blockers

A different class, the FcRn inhibitors (efgartigimod is the most widely known), works by accelerating the body’s clearance of IgG antibodies. Normally, a recycling receptor called FcRn rescues IgG from degradation, extending its lifespan in the blood. Blocking that receptor causes IgG levels, including the pathogenic autoantibodies, to drop rapidly.¹³ A meta-analysis of FcRn inhibitor trials found significant improvements across daily-living scores, strength measures, composite scores, and quality-of-life measures compared to placebo, without increasing the rate of serious side effects.¹⁴

A propensity-matched real-world comparison between complement inhibitors and FcRn blockers found that the two classes produced comparable improvements in daily-living scores and secondary outcomes.¹⁵ Because FcRn blockers lower all IgG rather than just targeting complement, they carry a theoretical risk of reduced immunity to infections, though trial data so far have not shown a clear signal of increased serious infections. One interesting mechanistic finding is that efgartigimod may do more than just clear antibodies: research suggests it also promotes the development of non-pathogenic regulatory plasma cells, which could contribute to its clinical benefit.¹⁶

B-Cell Depletion With Rituximab

Rituximab, which targets the CD20 protein on B cells and wipes out a major part of the antibody-producing immune cell line, has become a particularly important treatment for MuSK-antibody MG. A meta-analysis found that about 82% of MuSK-MG patients treated with rituximab achieved minimal symptoms or better, and roughly 56% reached complete stable remission or pharmacologic remission, with few serious adverse events.¹⁷ An earlier long-term follow-up study confirmed that all six MuSK-MG patients treated with rituximab achieved remission or minimal manifestations, with steroid doses dramatically reduced and other immunosuppressants withdrawn entirely. No reinfusions were needed, and three of six patients became MuSK-antibody negative.¹⁸ Those results in MuSK disease are far more impressive than what rituximab typically achieves in acetylcholine receptor antibody-positive disease, where it is used off-label but with less consistent responses.

Ocular Myasthenia Gravis

When MG affects only the eye muscles, causing drooping eyelids and double vision without generalized weakness, it is classified as ocular MG. About half of patients with ocular MG will eventually develop generalized disease, usually within the first two years. Treatment decisions here revolve partly around whether to start immunosuppressive therapy early to prevent that spread. A meta-analysis found that immunosuppressive therapy reduced the risk of generalization by about 77% compared with control groups.¹⁹ A separate study found that among those who did generalize, the median time to progression was about 3 years in the immunosuppressant group versus 1.7 years without it.²⁰ These findings push toward early treatment, even though many neurologists still take a wait-and-see approach in purely ocular cases that respond well to pyridostigmine alone.

Medications That Can Make MG Worse

One of the more overlooked aspects of MG management is the long list of common medications that can interfere with neuromuscular transmission and trigger dangerous flares. Certain antibiotics (particularly aminoglycosides and fluoroquinolones), some heart rhythm medications, certain anesthetics, and neuromuscular blocking agents used during surgery can all cause increased weakness or unmask MG-like symptoms even in people who haven’t been diagnosed.²¹ Anyone with MG should carry an alert card or wear a medical bracelet, and every prescribing physician and anesthesiologist needs to know about the diagnosis before writing a prescription or starting a procedure.

Treatment in Children

Juvenile MG follows a similar treatment ladder to adult disease, with pyridostigmine as first-line symptomatic treatment and oral prednisolone as first-line immunosuppression when symptoms aren’t adequately controlled. Children who don’t respond to steroids, can’t tolerate them, or can’t wean to a reasonable dose move on to azathioprine or mycophenolate. MuSK-positive juvenile MG, which tends to respond poorly to pyridostigmine, may warrant rituximab as second-line therapy. Thymectomy is recommended for any child with a thymoma and is considered in acetylcholine receptor-positive children, though clinicians generally allow time for the possibility of spontaneous remission, which occurs more often in childhood-onset disease.²²

A U.S. claims-database study found that MG exacerbations were most frequent in the first year after diagnosis in both prepubertal and postpubertal children. Corticosteroids were started earlier in postpubertal-onset patients (a median of about 1.3 months from diagnosis versus about 3.2 months for prepubertal-onset patients), and thymectomy rates were highest among children already receiving maintenance IVIG or plasma exchange.²³

Pregnancy Considerations

MG can be unpredictable during pregnancy, with some women improving and others worsening. A key concern is transient neonatal myasthenia gravis, caused by maternal antibodies crossing the placenta and temporarily affecting the baby. A systematic review found that pre-pregnancy thymectomy and the use of intravenous immunoglobulins during pregnancy can reduce this risk.²⁴ Not all immunosuppressants are safe during pregnancy: mycophenolate is known to cause birth defects and must be stopped well before conception, while azathioprine and low-dose prednisone are generally considered acceptable under close monitoring. Planning pregnancy in consultation with both a neurologist and an obstetrician is essential.

Vaccination Safety

People with MG are often anxious about vaccines triggering a flare, and some clinicians have historically been hesitant. The evidence is reassuring. A comprehensive review concluded that inactivated and subunit vaccines are safe in MG patients and that their immune response is comparable to the general population’s, so standard vaccinations should be recommended.²⁵ A placebo-controlled trial of influenza vaccination specifically confirmed that the vaccine did not raise acetylcholine receptor antibody levels and did not trigger MG symptom worsening, even in patients on immunosuppressive therapy.²⁶ Live vaccines are a different story and are generally avoided in immunosuppressed individuals, but most modern vaccines, including the mRNA COVID-19 vaccines, are non-live and fall into the safe category.

Exercise and Physical Rehabilitation

There is a persistent belief that people with MG should avoid exercise to prevent fatigue. Research suggests otherwise. A 12-week supervised program of aerobic and resistance training in 11 MG patients led to measurable improvements in muscle force, muscle thickness, and functional performance tests for leg muscles, along with improvements in composite MG clinical scores. No worsening of disease was observed.²⁷ Another feasibility study found that resistance training increased maximal strength and functional capacity in MG patients.²⁸ These are small studies, but the direction is consistent: moderate, supervised exercise appears to be safe and beneficial. The key is tailoring intensity to how the person feels day to day and avoiding exercising during a flare or a period of poorly controlled symptoms.

CAR-T Cell Therapy on the Horizon

The most dramatic experimental development is the use of CAR-T cell therapy, which reprograms a patient’s own immune cells to hunt down and destroy the B cells and plasma cells that produce pathogenic antibodies. This approach has transformed blood cancer treatment, and early trials in MG suggest it could do something similar for autoimmune disease.

A phase 1 trial of dual-target BCMA/CD19 CAR-T cells in 17 patients with refractory generalized MG reported no dose-limiting toxicities, no neurotoxicity, and only mild cytokine release syndrome. By six months, daily-living scores had dropped by an average of about 8.6 points and strength scores by about 15 points. Fourteen of 17 patients (82%) achieved minimal manifestations, 88% stopped steroids entirely, and all stopped non-steroidal immunosuppressants. Nearly half became seronegative for acetylcholine receptor antibodies.²⁹ A smaller study of six refractory patients using a similar BCMA/CD19 approach found that five achieved drug-free remission with minimal manifestations by six months, persisting through 12 months of follow-up despite B cells eventually returning.³⁰

A separate approach used RNA-based CAR-T cells (which are shorter-lived by design, reducing the risk of prolonged immune suppression) targeting only BCMA. That phase 1b/2a trial showed meaningful improvements in symptom scales at 12 weeks, with effects lasting up to nine months and no cytokine release syndrome or neurotoxicity.³¹ These are very early and very small trials, but the results are striking, especially in patients who had failed multiple prior treatments. Whether the remissions will last years or require retreatment, and whether these therapies can be manufactured at scale and at manageable cost, are open questions.

The Cost Problem With Newer Treatments

The targeted biologics currently on the market come with breathtaking price tags. A cost-effectiveness analysis estimated that lifetime treatment with eculizumab costs about $5.5 million per patient and efgartigimod about $6.8 million, compared with roughly $300,000 for conventional therapy. The incremental cost per quality-adjusted life year gained was over $3.3 million for eculizumab and about $2 million for efgartigimod, far above the thresholds typically considered acceptable by health economists.³² A separate cost-per-responder analysis found that intravenous efgartigimod had the lowest cost per improved patient among the current biologics, though “lowest” in this context still means expensive.³³

This creates a real access problem. Insurance coverage for these drugs often requires documented failure of conventional treatments, and approval processes can take months. For patients in the U.S. without robust insurance, or for patients in countries where these drugs aren’t yet approved or reimbursed, the practical treatment landscape remains conventional immunosuppression, thymectomy, and rescue therapies. The arrival of biosimilars for some complement inhibitors and competition among FcRn blockers may eventually push prices down, but for now, many MG patients who could benefit from targeted biologics simply cannot access them.

Seronegative and Double-Seronegative MG

A small but frustrating subset of patients test negative for both acetylcholine receptor and MuSK antibodies. This double-seronegative group poses diagnostic and therapeutic challenges because the antibody-targeted biologics are typically approved only for antibody-positive disease. A systematic review of double-seronegative cases found that standard treatments, particularly pyridostigmine (used in 84% of cases) and corticosteroids (76%), were still the mainstay. Outcomes were generally favorable, especially for those treated with plasmapheresis, rituximab, or tacrolimus, and no severe treatment-related adverse events were reported.³⁴ Some of these patients likely have antibodies that current commercial tests simply cannot detect, and as assay technology improves, this group is expected to shrink. For now, treatment is essentially empirical: try the standard drugs and escalate based on response.